1 completed, 1 recruiting. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Hua Zhang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar) - Unresectable Non-small Cell Lung Cancer | Phase 2 | Recruiting | Hua Zhang | 36 | 2024-08-27 | 2025-07-15 |
| Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Telbivudine, Lamivudine - Hepatitis B Infection, Chronic Infection | Phase 4 | Completed | Hua Zhang | 700 | 2009-03-01 | 2013-07-30 |
Hepatitis B (1) · Persistent Infection (1) · Viremia (1)
Drug Therapy (1) · Endostatins (1) · Lamivudine (1) · Surgical Procedures, Operative (1) · Telbivudine (1) · endostar protein (1)
China (1)